Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Launches High-Concentration Adalimumab In Europe

Plans To ‘Progressively’ Roll Out 100mg/ml Version Of Hyrimoz Biosimilar To Humira

Executive Summary

Sandoz has launched the high-concentration version of its Hyrimoz adalimumab biosimilar rival to Humira in Europe.

You may also be interested in...



Sandoz Benefits From Betting Big On Biosimilars

Sandoz’s biosimilars business was a big earner for the company in 2023. During the firm’s Q4 results call, CEO Richard Saynor provided a detailed breakdown of key products in the biosimilars portfolio and pipeline, as he highlighted sales growth of 26% in the most recent quarter.

A Year Of Change: Sandoz Completes A Transformational 2023

An eventful 2023 for Sandoz saw multiple major deals and key launches, with the year culminating in the firm’s long-awaited spinoff from parent company Novartis in October.

CVS Lines Up Sandoz’s Adalimumab Biosimilar For US Biosimilars Subsidiary

CVS feels its newly launched, wholly owned US biosimilars subsidiary called Cordavis is a “logical evolution for us and will help ensure sufficient supply of biosimilars in the US and support this market now and in the future.”

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel